REMBRANDT: REcovery of the MicroBiome fRom Antibiotics for Dental implanTs

Launched by UNIVERSITY OF PENNSYLVANIA · Nov 16, 2022

Keywords

ClinConnect Summary

The REMBRANDT trial is studying how owning pets might help protect against a serious gut infection called Clostridioides difficile (C. difficile), which can occur after taking antibiotics. Antibiotics can disrupt the normal balance of bacteria in the gut, leading to a condition known as dysbiosis, where harmful bacteria can grow. Researchers believe that the healthy bacteria shared between pets and their owners might help prevent this infection and improve gut health after antibiotic use. The study aims to better understand how pet ownership can influence these conditions and explore non-invasive ways to improve treatment through animal contact.

To participate in this trial, individuals must be at least 18 years old and currently receiving a dental implant. They should be able to understand the study procedures and comply with them throughout the trial. However, those who have been hospitalized or taken antibiotics in the last three months, have certain gastrointestinal illnesses, or have a history of C. difficile infection in the past year cannot join. Participants will be part of a study that looks at their gut health and may experience regular check-ins to assess their health and the impact of their pet on their well-being throughout the trial.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 18 years of age or older.
• • Receiving a dental implant.
• • Ability to understand study procedures and to comply with them for the entire length of the study.
• Exclusion Criteria:
• • Antimicrobial therapy or hospitalization in the prior three months;
• • Any gastrointestinal illness or underlying pathology (e.g., Inflammatory Bowel Disease, gastric ulceration)
• • Sustained diarrheal disease (i.e., at least 3 episodes of loose or watery stool per day for 3 or more days) in the prior 3 months;
• • Prior history of CDI in the prior year;
• • Immunomodulating medication (e.g., tumor necrosis factor inhibitors or systemic steroids) or conditions (e.g., leukemia)
• • Inability or unwillingness of individual or legal guardian/representative to give written informed consent.